Xingyuan Wang

962 total citations
37 papers, 677 citations indexed

About

Xingyuan Wang is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Xingyuan Wang has authored 37 papers receiving a total of 677 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Surgery, 13 papers in Pulmonary and Respiratory Medicine and 13 papers in Oncology. Recurrent topics in Xingyuan Wang's work include Cancer Immunotherapy and Biomarkers (8 papers), Esophageal Cancer Research and Treatment (6 papers) and Pancreatic and Hepatic Oncology Research (5 papers). Xingyuan Wang is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Esophageal Cancer Research and Treatment (6 papers) and Pancreatic and Hepatic Oncology Research (5 papers). Xingyuan Wang collaborates with scholars based in China, United States and Canada. Xingyuan Wang's co-authors include Jing Huang, Hongnan Mo, Dawei Wu, Dong Qu, Xuelian Chen, Bo Lan, Jianping Xu, Qing Yang, Binghe Xu and Bo Zhang and has published in prestigious journals such as Cancer, Scientific Reports and Clinical Cancer Research.

In The Last Decade

Xingyuan Wang

37 papers receiving 667 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xingyuan Wang China 11 428 249 242 119 91 37 677
Vittorio Branchi Germany 15 277 0.6× 274 1.1× 188 0.8× 200 1.7× 162 1.8× 41 685
Alexander Krohn Germany 11 369 0.9× 118 0.5× 168 0.7× 183 1.5× 83 0.9× 27 646
Jiayu Ling China 10 321 0.8× 142 0.6× 113 0.5× 119 1.0× 134 1.5× 39 597
Dong Yi Kim South Korea 15 259 0.6× 328 1.3× 435 1.8× 159 1.3× 36 0.4× 43 896
Masahiro Kitada Japan 15 210 0.5× 194 0.8× 185 0.8× 103 0.9× 105 1.2× 91 599
Akihiko Kobayashi Japan 15 245 0.6× 167 0.7× 148 0.6× 194 1.6× 75 0.8× 40 634
Xiong Lei China 15 212 0.5× 159 0.6× 143 0.6× 248 2.1× 64 0.7× 38 629
L-T. Chen Taiwan 17 299 0.7× 233 0.9× 238 1.0× 252 2.1× 112 1.2× 47 906
Tse-Ching Chen Taiwan 15 217 0.5× 160 0.6× 131 0.5× 204 1.7× 66 0.7× 21 629
Bin Jiang China 16 282 0.7× 144 0.6× 101 0.4× 173 1.5× 85 0.9× 61 663

Countries citing papers authored by Xingyuan Wang

Since Specialization
Citations

This map shows the geographic impact of Xingyuan Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xingyuan Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xingyuan Wang more than expected).

Fields of papers citing papers by Xingyuan Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xingyuan Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xingyuan Wang. The network helps show where Xingyuan Wang may publish in the future.

Co-authorship network of co-authors of Xingyuan Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Xingyuan Wang. A scholar is included among the top collaborators of Xingyuan Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xingyuan Wang. Xingyuan Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Xingyuan, Dechao Li, Lichen Teng, et al.. (2024). Pazopanib stimulates senescence of renal carcinoma cells through targeting nuclear factor E2‐related factor 2 (Nrf2). Journal of Biochemical and Molecular Toxicology. 38(4). e23689–e23689. 2 indexed citations
2.
Zhang, Xuyan, Qingrong Li, Xingyuan Wang, et al.. (2024). Signal peptide replacement of Ag43 enables an efficient bacterial cell surface display of receptor-binding domain of coronavirus. Biochemical and Biophysical Research Communications. 721. 150146–150146. 1 indexed citations
3.
4.
Xie, Tongji, Yan Li, Lei Guo, et al.. (2023). Low TP53 variant allele frequency as a biomarker for anti‐programmed death (ligand) 1 monotherapy in lung adenocarcinoma. Cancer. 129(24). 3873–3883. 2 indexed citations
5.
Li, Zhiyuan, Zhinan Xia, Yipeng Yu, et al.. (2022). A pyroptosis-associated signature plays a role in prognosis prediction in clear cell renal cell carcinoma. BMC Medical Genomics. 15(1). 204–204. 3 indexed citations
6.
Zheng, Weitao, Ming Shi, Tao Li, et al.. (2021). Giant bilateral primary scrotal lipoma along with lipomas in multiple sites of the body: a case report and literature review. Translational Andrology and Urology. 10(2). 983–990. 7 indexed citations
7.
Chen, Zeyu, Xingyuan Wang, Liang Zhou, et al.. (2021). Body Composition Parameters May Be Prognostic Factors in Upper Urinary Tract Urothelial Carcinoma Treated by Radical Nephroureterectomy. Frontiers in Oncology. 11. 679158–679158. 6 indexed citations
8.
Liu, Yun, Bo Zhang, Jianping Xu, et al.. (2021). Phase I study of liposomal irinotecan (LY01610) in patients with advanced esophageal squamous cell carcinoma. Cancer Chemotherapy and Pharmacology. 88(3). 403–414. 8 indexed citations
9.
Wang, Xingyuan, Zeyu Chen, Shi Qiu, et al.. (2021). Clinical Characteristics and Prognostic Factors of Testicular Sarcoma: A Population-Based Study. Frontiers in Oncology. 11. 614093–614093. 1 indexed citations
10.
Zhang, Bo, Ling Qi, Xi Wang, et al.. (2020). Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first‐line treatment of advanced esophageal squamous cell carcinoma. Cancer Communications. 40(12). 711–720. 91 indexed citations
11.
Wang, Xingyuan, Zeyu Chen, Shi Qiu, et al.. (2020). <p>Evaluating the Effect of Cryptorchidism on Clinical Stage of Testicular Seminoma</p>. Cancer Management and Research. Volume 12. 4883–4888. 2 indexed citations
12.
Tang, Yizhi, et al.. (2020). Genetic environments and related transposable elements of novel cfr(C) variants in Campylobacter coli isolates of swine origin. Veterinary Microbiology. 247. 108792–108792. 10 indexed citations
13.
Zhang, Bo, Xi Wang, Qun Li, et al.. (2019). Efficacy of irinotecan-based chemotherapy after exposure to an anti-PD-1 antibody in patients with advanced esophageal squamous cell carcinoma. Chinese Journal of Cancer Research. 31(6). 910–917. 13 indexed citations
14.
Han, Xiaohong, Sheng Yang, Junling Li, et al.. (2019). Comprehensive Profiling of Gene Copy Number Alterations Predicts Patient Prognosis in Resected Stages I–III Lung Adenocarcinoma. Frontiers in Oncology. 9. 556–556. 23 indexed citations
15.
Huang, Jing, Binghe Xu, Hongnan Mo, et al.. (2018). Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma. Clinical Cancer Research. 24(6). 1296–1304. 149 indexed citations
16.
17.
Mo, Hongnan, Jing Huang, Jiachen Xu, et al.. (2018). Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study. British Journal of Cancer. 119(5). 538–545. 122 indexed citations
18.
19.
Wang, Xingyuan, et al.. (2016). Bladder cancer cells induce immunosuppression of T cells by supporting PD‐L1 expression in tumour macrophages partially through interleukin 10. Cell Biology International. 41(2). 177–186. 42 indexed citations
20.
Wang, Xingyuan, Quanxing Ni, Maolin Jin, et al.. (2002). Gemcitabine or gemcitabine plus cisplatin for in 42 patients with locally advanced or metastatic pancreatic cancer.. PubMed. 24(4). 404–7. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vittorio Branchi Breakdown of academic impact, for papers by Alexander Krohn Breakdown of academic impact, for papers by Jiayu Ling Breakdown of academic impact, for papers by Dong Yi Kim Breakdown of academic impact, for papers by Masahiro Kitada Breakdown of academic impact, for papers by Akihiko Kobayashi Breakdown of academic impact, for papers by Xiong Lei Breakdown of academic impact, for papers by L-T. Chen Breakdown of academic impact, for papers by Tse-Ching Chen Breakdown of academic impact, for papers by Bin Jiang
Rankless by CCL
2026